Faron Pharmaceuticals: Correction: Faron Pharmaceuticals Ltd’s Annual Report 2025 published

Faron Pharmaceuticals OyAnnouncement

Yesterday 16:45

Faron Pharmaceuticals Ltd | Company announcement | March 04, 2026 at 18:45:00
EET

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON),
announces a correction to the company announcement of its Annual Report 2025,
originally published on 4 March 2026 at 09:15 EET
(https://faron.com/releases-and-publications/faron-pharmaceuticals-ltds-annual-report-2025-published/).
The Annual Report 2025 published did not contain the auditor’s report. An
updated version of the Annual Report 2025 with the full auditor's report, has
been included as an attachment to this announcement.

The English version of Annual Report is available as a PDF file attached to
this release and on the company’s website
at https://faron.com/investors/reports-and-presentations/. Also the Finnish
language version of the Financial Statements is available as a PDF file
attached to this release and on the company’s website
at https://faron.fi/sijoittajat/raportit-esitykset/.

Faron Pharmaceuticals Ltd
Board of Directors

For more information please contact:

IR Partners, Finland
(Media)
Kare Laukkanen
Phone: +358 50 553 9535
E-mail: kare.laukkanen@irpartners.fi

FINN Partners, US
(Media)
Alyssa Paldo
Phone: +1 847 791-8085
E-mail: alyssa.paldo@finnapartners.com

Cairn Financial Advisers LLP, Nominated Adviser and Broker
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880

Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990

About BEXMAB
The BEXMAB study is an open-label Phase I/II clinical trial investigating
bexmarilimab in combination with standard of care (SoC) in the aggressive
hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). The primary objective is to determine the safety and
tolerability of bexmarilimab in combination with SoC (azacitidine) treatment.

About Bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments by targeting Clever-1, a
receptor on immunosuppressive macrophages and malignant blasts. By inhibiting
Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a
potent anti-tumor immune response.

About Faron Pharmaceuticals Ltd.
Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global,
clinical-stage biopharmaceutical company, focused on creating innovative
cancer treatments that leverage the patient’s own immune system. The Company’s
lead asset bexmarilimab is currently being investigated in multiple clinical
trials as a potential therapy for patients with hematological malignancies and
solid tumors in combination with other standard treatments.

Forward-Looking Statements
This press release contains certain forward-looking statements relating to the
business of Faron Pharmaceuticals. In addition, even if the actual results or
development of Faron Pharmaceuticals are consistent with the forward-looking
statements contained in this press release, those results or developments of
Faron Pharmaceuticals may not be sustained in the future. In some cases, you
can identify forward-looking statements by words such as “could,” “should,”
“may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,”
“targets,” or similar words. These forward-looking statements are based
largely on the current expectations of Faron Pharmaceuticals as of the date of
this press release and are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from any future results, performance
or achievement expressed or implied by these forward-looking statements. In
particular, the expectations of Faron Pharmaceuticals could be affected by,
among other things, uncertainties and delays involved in the development of
product candidates, unexpected clinical trial results, unexpected regulatory
actions or delays, competition in general, currency fluctuations, inflation,
changes in tariff policies, political or macroeconomic developments, and the
ability to obtain or maintain patent or other proprietary intellectual
property protection. Success in preclinical studies or earlier clinical trials
may not be indicative of results in future clinical trials. In light of these
risks and uncertainties, there can be no assurance that the forward-looking
statements made in this press release will in fact be realized. Faron
Pharmaceuticals is providing this information as of the date of this press
release and disclaims any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise.

THE NEW SHARES ISSUED IN THE RIGHTS OFFERING WILL NOT BE REGISTERED UNDER THE
UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED
STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY,
IN OR INTO OR FROM THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY
STATE OR OTHER JURISDICTION OF THE UNITED STATES.

Attachments
Faron Tilinpäätös 2025 040326
(https://storage.mfn.se/3e3af889-9c90-4812-8737-736af2757aea/faron-tilinpaatos-2025-040326.pdf)
Faron Annual Report 2025 040326
(https://storage.mfn.se/51f40344-ee44-49e6-8d87-8fd0404e42e2/faron-annual-report-2025-040326.pdf)